Compare Oscar Health Inc (OSCR) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Synopsys, Inc. — how do they compare? Oscar Health Inc trades at $33.83 (market cap $10.22B), while Synopsys, Inc. trades at $510.17 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 9.3× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Synopsys, Inc. for 71 Days on average.
| OSCR | SNPS | |
|---|---|---|
Market Cap | $10.22B | $95.39B |
Volume | 4,123,394 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $33.81 | $534.56 |
52-Week Low | $10.85 | $367.70 |
Typical Hold Time | 15 Days | 71 Days |
Enterprise Value | $6.57B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $32.91, up 1.76% today, with a bullish technical outlook from moving averages and mixed oscillators. The stock shows strong revenue growth, with 2026 revenue projected at $15.3B, and profitability turning positive with a net income margin of 3.59%. Recent news highlights market share gains in the ACA sector and raised 2026 guidance, though Q3 2026 EPS is yet to be reported.
The outlook is positive with analyst consensus at Buy and a $34 price target, but risks include rising medical costs and execution challenges. Upside potential exists from scalable growth and margin expansion, yet volatility near resistance levels and competitive pressures warrant caution for investors.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights AI-driven partnerships with OpenAI and Amazon, boosting growth prospects. Valuation ratios are elevated, with a P/E of 86.87, reflecting high growth expectations. Analyst sentiment is overwhelmingly positive, with a consensus price target of $572.54.
The outlook for SNPS is favorable, driven by AI integration and strategic acquisitions, but risks include high valuation sensitivity and competitive pressures. Revenue growth and margin expansion from new deals present opportunities, though investors should monitor execution risks and market volatility. The stock's proximity to key resistance levels suggests potential for near-term consolidation or breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
